Pfizer asks FDA to authorize second booster for older adults

Mar 16, 2022 - 03:03 PM

Pfizer yesterday asked the Food and Drug Administration to authorize a second booster dose of its COVID-19 vaccine for adults age 65 and older who received an initial booster of any authorized or approved COVID-19 vaccine, based on data from Israel showing the additional booster reduced infections and severe illness when the omicron variant was circulating.

Related News Articles

Headline
FDA issues updated EUA for bivalent booster doses to fight omicron; providers to cease administration of monovalent boosters
The Food and Drug Administration yesterday announced it has amended the emergency use authorizations for Pfizer’s and Moderna’s COVID-19 vaccines to…
Headline
Pfizer applies for EUA for variant-tailored booster; unveils new efficacy data for youngest children
Pfizer yesterday announced its application for an emergency use authorization for a COVID-19 vaccine booster that is designed to protect against the SARS-CoV-2…
Headline
FDA expands Novavax EUA to include children 12 and older
Novavax today announced the Food and Drug Administration expanded the emergency use authorization for its Adjuvanted (NVX-CoV2373) COVID-19 vaccine. Under…
Headline
FDA recommends repeating COVID-19 at-home test in 48 hours if negative
The Food and Drug Administration yesterday advised people who get a negative result from an at-home COVID-19 antigen test to test themselves again after…
Headline
CDC updates public health guidance for preventing COVID-19 illness
The Centers for Disease Control and Prevention today released updated guidance to help people protect themselves and others if they are exposed to, sick or…
Headline
Blog: 5 thoughts on the state of COVID-19 vaccination and the road ahead  
Hospital leaders from the AHA’s vaccine confidence initiative share tips for building COVID-19 vaccine confidence. “Getting more Americans vaccinated against…